Nature's Sunshine Products (NATR) 10-Q 6 May 21 2021 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2021	Apr. 30, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2021
Document Transition Report	false
Entity File Number	001-34483
Entity Registrant Name	NATURE’S SUNSHINE PRODUCTS, INC.
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	87-0327982
Entity Address, Address Line One	2901 Bluegrass Boulevard
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Lehi
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84043
City Area Code	801
Local Phone Number	341-7900
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	NATR
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,946,557
Entity Central Index Key	0000275053
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 91,253	$ 92,069
Accounts receivable, net of allowance for doubtful accounts of $451 and $454, respectively	9,858	7,375
Inventories	46,510	47,683
Prepaid expenses and other	7,178	6,938
Total current assets	154,799	154,065
Property, plant and equipment, net	52,552	54,355
Operating lease right-of-use assets	18,884	20,210
Investment securities - trading	971	989
Deferred income tax assets	7,915	8,693
Other assets	10,710	11,186
Total assets	245,831	249,498
Current liabilities:
Accounts payable	6,939	6,486
Accrued volume incentives and service fees	20,808	19,481
Accrued liabilities	25,104	31,710
Accrued dividends payable	19,858	0
Deferred revenue	1,673	2,092
Related party notes payable	1,221	1,200
Income taxes payable	1,678	2,387
Current portion of operating lease liabilities	4,629	4,992
Current portion of note payable	1,216	1,306
Total current liabilities	83,126	69,654
Liability related to unrecognized tax benefits	82	92
Long-term portion of operating lease liabilities	15,577	16,412
Long-term note payable	2,110	2,418
Deferred compensation payable	971	989
Deferred income tax liabilities	1,241	1,391
Other liabilities	1,226	1,308
Total liabilities	104,333	92,264
Shareholders’ equity:
Common stock, no par value, 50,000 shares authorized, 19,915 and 19,697 shares issued and outstanding, respectively	139,402	139,311
Retained earnings	10,188	26,030
Noncontrolling interest	1,984	1,848
Accumulated other comprehensive loss	(10,076)	(9,955)
Total shareholders’ equity	141,498	157,234
Total liabilities and shareholders’ equity	$ 245,831	$ 249,498

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 451	$ 454
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	19,915,000	19,697,000
Common stock, shares outstanding (in shares)	19,915,000	19,697,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Net sales	$ 102,421	$ 95,926
Cost of sales	26,979	24,681
Gross profit	75,442	71,245
Operating expenses:
Volume incentives	34,255	33,018
Selling, general and administrative	33,552	31,065
Operating income	7,635	7,162
Other loss, net	(1,933)	(2,410)
Income before provision for income taxes	5,702	4,752
Provision for income taxes	1,550	1,746
Net income	4,152	3,006
Net income attributable to noncontrolling interests	136	44
Net income attributable to common shareholders	$ 4,016	$ 2,962
Basic and diluted net income per common share:
Basic earnings per share attributable to common shareholders (in dollars per share)	$ 0.20	$ 0.15
Diluted earnings per share attributable to common shareholders (in dollars per share)	$ 0.20	$ 0.15
Weighted average basic common shares outstanding (in shares)	19,794	19,453
Weighted average diluted common shares outstanding (in shares)	20,236	19,589
Dividends declared per common share (in dollars per share)	$ 1	$ 0

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Net income	$ 4,152	$ 3,006
Foreign currency translation loss (net of tax)	(121)	(109)
Total comprehensive income	$ 4,031	$ 2,897

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Retained Earnings	Noncontrolling Interest	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2019		19,410,000
Beginning balance at Dec. 31, 2019	$ 129,436	$ 135,741	$ 4,693	$ 227	$ (11,225)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	394	$ 394
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		60,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(159)	$ (159)
Net income	3,006		2,962	44
Other comprehensive loss	(109)				(109)
Ending balance (in shares) at Mar. 31, 2020		19,470,000
Ending balance at Mar. 31, 2020	$ 132,568	$ 135,976	7,655	271	(11,334)
Beginning balance (in shares) at Dec. 31, 2020	19,697,000	19,697,000
Beginning balance at Dec. 31, 2020	$ 157,234	$ 139,311	26,030	1,848	(9,955)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	1,005	$ 1,005
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		218,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(914)	$ (914)
Cash dividends	(19,858)		(19,858)
Net income	4,152		4,016	136
Other comprehensive loss	$ (121)				(121)
Ending balance (in shares) at Mar. 31, 2021	19,915,000	19,915,000
Ending balance at Mar. 31, 2021	$ 141,498	$ 139,402	$ 10,188	$ 1,984	$ (10,076)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (PARENTHETICAL) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Stockholders' Equity [Abstract]
Cash dividend (in dollars per share)	$ 1	$ 0

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 4,152	$ 3,006
Adjustments to reconcile net income to net cash provided by operating activities:
Provision for doubtful accounts	0	17
Depreciation and amortization	2,736	2,602
Non-cash lease expense	1,311	1,270
Share-based compensation expense	1,005	394
Tax benefit from the exercise of stock options	0	159
Loss on sale of property, plant and equipment	0	6
Deferred income taxes	561	249
Purchase of trading investment securities	(16)	(11)
Proceeds from sale of trading investment securities	175	73
Realized and unrealized (gains) losses on investments	(16)	96
Foreign exchange losses	1,529	2,400
Changes in assets and liabilities:
Accounts receivable	(2,689)	1,318
Inventories	536	234
Prepaid expenses and other current assets	(272)	165
Other assets	24	31
Accounts payable	598	704
Accrued volume incentives and service fees	1,644	4,356
Accrued liabilities	(6,248)	(2,206)
Deferred revenue	(394)	406
Lease liabilities	(1,170)	(1,187)
Income taxes payable	(699)	(335)
Liability related to unrecognized tax positions	(10)	(73)
Deferred compensation payable	(22)	(158)
Net cash provided by operating activities	2,735	13,516
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(983)	(1,209)
Net cash used in investing activities	(983)	(1,209)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments of long-term debt	(397)	0
Payments related to tax withholding for net-share settled equity awards	(914)	0
Tax benefit from exercise of stock options	0	(159)
Net cash used in financing activities	(1,311)	(159)
Effect of exchange rates on cash and cash equivalents	(1,257)	(1,632)
Net increase (decrease) in cash and cash equivalents	(816)	10,516
Cash and cash equivalents at the beginning of the period	92,069	53,629
Cash and cash equivalents at the end of the period	91,253	64,145
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes, net of refunds	2,026	1,224
Cash paid for interest	$ 50	$ 3

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent consultants who uses the products themselves or resells them to consumers. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of March 31, 2021, and for the three-month periods ended March 31, 2021 and 2020. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2021. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020. Use of Estimates The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors and those differences could have a material effect on our financial position and results of operations. The significant accounting estimates inherent in the preparation of our financial statements include estimates associated with our determination of liabilities related to independent consultant incentives, the determination of income tax assets and liabilities, certain other non-income tax and value-added tax contingencies, and legal contingencies. In addition, significant estimates form the basis for allowances with respect to inventory valuations. Various assumptions and other factors enter into the determination of these significant estimates. The process of determining significant estimates takes into account historical experience and current and expected economic conditions. Noncontrolling Interests Noncontrolling interest changed as a result of the net income attributable to noncontrolling interest of $0.1 million and $44,000 for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021 and December 31, 2020, noncontrolling interest was $2.0 million and $1.8 million, respectively. Restructuring Related Accruals and Expenses We recorded $48,000 and $0.1 million of restructuring related expenses during the three months ended March 31, 2021 and 2020, respectively. Accrued severance and restructuring related costs were $0.1 million and $0.4 million as of March 31, 2021 and December 31, 2020, respectively. Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This ASU eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the quarters and the recognition of deferred tax liabilities for outside basis differences. The amendments in this update are effective for reporting periods beginning after December 15, 2020, with early adoption permitted. The adoption of this ASU did not have a significant impact on our Consolidated Financial Statements. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories The composition of inventories is as follows (dollar amounts in thousands): March 31, December 31, Raw materials $ 14,075 $ 13,956 Work in progress 1,783 1,351 Finished goods 30,652 32,376 Total inventories $ 46,510 $ 47,683

Investment Securities - Trading

Investment Securities - Trading	3 Months Ended
	Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Investment Securities - Trading	Investment Securities - Trading Our trading securities portfolio totaled $1.0 million at March 31, 2021, and $1.0 million at December 31, 2020; and generated gains of $16,000 and generated losses $0.1 million for the three months ended March 31, 2021 and 2020, respectively.

Revolving Credit Facility and O

Revolving Credit Facility and Other Obligations	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Revolving Credit Facility and Other Obligations	Revolving Credit Facility and Other Obligations On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million (the “Credit Agreement”). On June 11, 2020, the credit agreement was amended to extend the term to mature on July 1, 2023. The amendment also allows for additional borrowings of $15.0 million or up to three separate increases of no less than $5.0 million each. On March 8, 2021, we signed an amendment to the credit agreement that eliminates the Index floor from the calculation of interest. We pay interest on any borrowings under the Credit Agreement, which through March 8, 2021, was at LIBOR, or the Index floor of 0.75 percent, plus 2.25 percent (3.00 percent as of December 31, 2020), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. Interest under the amended Credit Agreement is at LIBOR, plus 2.25 percent (2.36 percent as of March 31, 2021), and an annual commitment fee of 0.25 percent on the unused portion of the commitment. We are required to settle our net borrowings under the Credit Agreement only upon maturity, and as a result, have classified prior outstanding borrowings as non-current on our condensed consolidated balance sheet. At March 31, 2021, there was no outstanding balance under the Credit Agreement. The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency and leverage. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, mergers, consolidations and transfers of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable balance, inventory balance and other assets. As of March 31, 2021, we were in compliance with the debt covenants set forth in the Credit Agreement. On April 21, 2020, we entered into a credit agreement with Banc of America Leasing and Capital, LLC, with a borrowing limit of $6.0 million (the "Capital Credit Agreement"). On November 19, 2020, we executed on the Capital Credit Agreement and borrowed $3.7 million. We do not expect to make any additional borrowings under the Capital Credit Agreement. We pay interest on any borrowings under the Capital Credit Agreement at a fixed rate of 3.00 percent and are required to settle our borrowings under the Capital Credit Agreement in thirty-six monthly payments, of $0.1 million The Capital Credit Agreement is collateralized by any new equipment purchased under the agreement. As of March 31, 2021, there was $3.3 million outstanding under the Capital Credit Agreement, $1.2 million of which was classified as current.

Net Income Per Share

Net Income Per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share. Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the Three months ended March 31, 2021 and 2020 (dollar and share amounts in thousands, except for per share information): Three Months Ended 2021 2020 Net income attributable to common shareholders $ 4,016 $ 2,962 Basic weighted average shares outstanding 19,794 19,453 Basic earnings per share attributable to common shareholders $ 0.20 $ 0.15 Diluted shares outstanding: Basic weighted-average shares outstanding 19,794 19,453 Stock-based awards 442 136 Diluted weighted-average shares outstanding 20,236 19,589 Diluted earnings per share attributable to common shareholders $ 0.20 $ 0.15 Dilutive shares excluded from diluted-per-share amounts: Stock options 629 850 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options — 214 Potentially dilutive shares excluded from diluted-per-share amounts include performance-based restricted stock units ("RSU"), for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted-average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.

Capital Transactions

Capital Transactions	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Capital Transactions	Capital Transactions Share-Based Compensation During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of Common Stock reserved for issuance by 1,500,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events. We have also maintained a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan"), which provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. Under the 2012 Incentive Plan, any shares subject to award, or awards forfeited or reacquired by the Company issued under the 2009 Incentive Plan are available for award up to a maximum of 400,000 shares. As of March 31, 2021, there were no outstanding awards under the 2009 Incentive Plan. Stock Options Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six, eight and ten percent as reported in four of five consecutive quarters over the term of the options. Stock option activity for the three-month period ended March 31, 2021, is as follows (amounts in thousands, except per share information): Number of Weighted Average Weighted Average Options outstanding at January 1, 2021 226 $ 12.10 $ 5.42 Granted — — — Forfeited or canceled — — — Exercised (2) 11.98 6.16 Options outstanding at March 31, 2021 224 12.10 5.41 There was no share-based compensation expense for the three-month periods ended March 31, 2021 and 2020. As of March 31, 2021 and December 31, 2020, there was no unrecognized share-based compensation expense related to the stock option grants described above. At March 31, 2021, the aggregate intrinsic value of outstanding and exercisable stock options to purchase 224,000 shares of common stock was $1.8 million. At December 31, 2020, the aggregate intrinsic value of outstanding and exercisable options to purchase 226,000 shares of common stock was $0.7 million. For the three-month period ended March 31, 2021, we issued 2,500 shares of common stock upon the exercise of stock options at an average exercise price of $11.98 per share. The aggregate intrinsic value of options exercised during the three-month periods ended March 31, 2021 was $19,000. For the three-month period ended March 31, 2021, the Company recognized $9,000 of tax benefits from the exercise of stock options. There were no stock options exercised during the three-month period ended March 31, 2020. As of March 31, 2021 and December 31, 2020, there were no unvested stock options outstanding. Restricted Stock Units Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to revenue and earnings growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At March 31, 2021 and December 31, 2020, there were 92,000 and 82,000 vested RSUs, respectively, granted to the Board of Directors with a restriction period. Restricted stock unit activity for the three-month period ended March 31, 2021, is as follows (amounts in thousands, except per share information): Number of Weighted Average Restricted Stock Units outstanding at January 1, 2021 1,179 $ 6.18 Granted 229 15.89 Forfeited (30) 11.25 Issued (291) 6.52 Restricted Stock Units outstanding at March 31, 2021 1,087 8.00 During the three-month period ended March 31, 2021, we granted 229,000 RSUs under the 2012 Incentive Plan to the executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $18.34 per share and vest in annual installments over a three-year period from the grant date. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $13.87 per share and vest upon achieving share-priced targets over a three-year period from the grant date. Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 12.7 percent for a common share. Share-price-performance RSU's market-value was estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years, expected volatility of between 50.0 percent and 54.7 percent, and a range of risk-free rates of between 0.3 percent and 2.9 percent. Share-based compensation expense for RSUs for the three-month periods ended March 31, 2021 and 2020, was approximately $0.4 million and $0.3 million, respectively. As of March 31, 2021 and December 31, 2020, the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $2.7 million and $1.3 million, respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.9 years. Share-based compensation expense related to performance-based RSUs for the three-month periods ended March 31, 2021 and 2020, was $0.4 million and $0.1 million, respectively. Should we attain all of the metrics related to performance-based RSU grants, we would recognize up to $2.7 million of potential share-based compensation expense. We currently expect to recognize an additional $2.6 million of that potential share-based compensation expense.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Information	Segment Information We have four business segments (Asia, Europe, North America, and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market. Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin by segment before consideration of certain inter-segment transfers and expenses. Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended 2021 2020 Net sales: Asia $ 35,755 $ 30,958 Europe 22,200 20,627 North America 37,762 38,757 Latin America and Other 6,704 5,584 Total net sales 102,421 95,926 Contribution margin (1): Asia 15,319 14,527 Europe 6,796 6,831 North America 15,440 14,419 Latin America and Other 3,632 2,450 Total contribution margin 41,187 38,227 Selling, general and administrative expenses (2) 33,552 31,065 Operating income 7,635 7,162 Other loss, net (1,933) (2,410) Income before provision for income taxes $ 5,702 $ 4,752 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in China totaled $2.8 million and $1.9 million for the three-month periods ended March 31, 2021 and 2020, respectively. These service fees are included in selling, general and administrative expenses. From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three-month periods ended March 31, 2021 and 2020, as follows (dollar amounts in thousands): Three Months Ended 2021 2020 Net sales: United States $ 34,920 $ 35,839 South Korea 14,809 16,389 Other 52,692 43,698 $ 102,421 $ 95,926 Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended 2021 2020 Asia General health $ 11,292 $ 9,046 Immune 203 201 Cardiovascular 9,903 9,339 Digestive 6,871 6,156 Personal care 2,524 3,005 Weight management 4,962 3,211 35,755 30,958 Europe General health $ 9,472 $ 7,961 Immune 2,016 2,444 Cardiovascular 2,992 2,897 Digestive 5,540 4,931 Personal care 1,426 1,751 Weight management 754 643 22,200 20,627 North America General health $ 16,270 $ 15,464 Immune 4,874 7,798 Cardiovascular 4,225 4,167 Digestive 9,463 8,241 Personal care 1,819 1,929 Weight management 1,111 1,158 37,762 38,757 Latin America and Other General health $ 1,976 $ 1,614 Immune 811 809 Cardiovascular 478 378 Digestive 2,870 2,362 Personal care 345 252 Weight management 224 169 6,704 5,584 $ 102,421 $ 95,926 From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): March 31, December 31, Property, plant and equipment: United States $ 48,693 $ 50,025 Other 3,859 4,330 Total property, plant and equipment, net $ 52,552 $ 54,355 Total assets per segment is set forth below (dollar amounts in thousands): March 31, December 31, Assets: Asia $ 84,668 $ 82,572 Europe 16,533 16,398 North America 135,710 142,324 Latin America and Other 8,920 8,204 Total assets $ 245,831 $ 249,498

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended March 31, 2021 and 2020, our provision for income taxes, as a percentage of income before income taxes was 27.2 percent and 36.7 percent, respectively, compared with a U.S. federal statutory rate of 21.0 percent. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three months ended March 31, 2021, was primarily attributed to transfer pricing adjustments and non-deductible executive compensation, partially offset by favorable deductions for stock compensation. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three months ended March 31, 2020, was primarily attributed to foreign losses during that period that were not expected to provide future tax benefit, as well as net unfavorable foreign tax related items. The difference between the effective tax rate for the three months ended March 31, 2021 compared to March 31, 2020 is primarily caused by a decrease in tax liability associated with foreign losses during each period and favorable deductions for stock compensation. Our U.S. federal income tax returns for 2017 through 2019 are open to examination for federal tax purposes. We have several foreign tax jurisdictions that have open tax years from 2015 through 2020. As of March 31, 2021 and December 31, 2020, we had accrued $0.1 million and $0.1 million, respectively, related to unrecognized tax positions. Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although we believe our tax estimates are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our historical income tax provisions and accruals. Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings We are party to various legal proceedings and disputes. Management cannot predict the ultimate outcome of these matters, individually or in the aggregate, or their resulting effect on our business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on our business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. We maintain product liability, general liability and excess liability insurance coverage. However, insurance may not continue to be available at an acceptable cost to us, such coverage may not be sufficient to cover one or more large claims, or the insurers may successfully disclaim coverage as to a pending or future claim. Non-Income Tax Contingencies We have reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. We provide provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. We provide provisions for U.S. state sales taxes in each of the states where we have nexus. As of March 31, 2021 and December 31, 2020, accrued liabilities were $0.2 million and $0.2 million, respectively, related to non-income tax contingencies. While we believe that the assumptions and estimates used to determine contingent liabilities are reasonable, the ultimate outcome of these matters cannot presently be determined. We believe future payments related to these matters could range from $0 to approximately $2.4 million. Other Litigation

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Related Party TransactionsDuring the three months ended March 31, 2021 and 2020, our joint venture in China, owned 80 percent by us and 20 percent by a wholly owned subsidiary of Fosun Pharma, did not borrow any amounts from the Company or our joint venture partner. As of March 31, 2021 and December 31, 2020 our joint venture in China held a note payable to the Company of $4.9 million and $4.8 million, respectively. As of March 31, 2021 and December 31, 2020 our joint venture held a note payable to our joint venture partner of $1.2 million and $1.2 million, respectively. These notes are payable in less than one year and bear interest of 3.0 percent. The note between the joint venture and the Company eliminates in consolidation.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of March 31, 2021 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 971 $ — $ — $ 971 Total assets measured at fair value on a recurring basis $ 971 $ — $ — $ 971 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2020 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 989 $ — $ — $ 989 Total assets measured at fair value on a recurring basis $ 989 $ — $ — $ 989 Investment securities - trading — Our trading portfolio consists of various marketable securities that are valued using quoted prices in active markets. For the three months ended March 31, 2021, and for the year ended December 31, 2020, there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3). The carrying amounts reflected on the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their short-term nature. The carrying value of our debt approximates fair value due to its recent acquisition and short maturity. During the three months ended March 31, 2021 and 2020, we did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Revenue Recognition Net sales include products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value-added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. A reserve for product returns is recorded based upon historical experience and current trends. We allow independent consultants to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return product are more restrictive. From time to time, our U.S. operations extend short-term credit associated with product promotions. In addition, for certain of our international operations, we offer credit terms consistent with industry standards within the country of operation. Volume incentives and other sales incentives or rebates are a significant part of our direct sales marketing program and represent commission payments made to independent consultants. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent consultants for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Some payments for sales incentives are processed daily; while others, including rebates, are calculated monthly based upon qualifying sales. Contract Liabilities - Customer Loyalty Programs We record contract liabilities for loyalty point programs in deferred revenue. These programs are accounted for as a reduction in the transaction price and are generally recognized as points that are redeemed for additional products. The following table presents changes in these contract liability balances for the three-month period ended March 31, 2021 (U.S. dollars in thousands): Outstanding at January 1, 2021 $ 983 Increase (decrease) attributed to: Customer loyalty net deferrals 258 Customer loyalty redemptions (257) Outstanding at March 31, 2021 $ 984 The table above excludes liability for sales returns, as they are not significant. Disaggregation of Revenue Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category. Practical Expedients and Exemptions We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606. We generally expense volume incentives when incurred because the amortization period would have been one year or less. All of our contracts with customers have a duration of less than one year. The value of any unsatisfied performance obligations is insignificant.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent consultants who uses the products themselves or resells them to consumers.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of March 31, 2021, and for the three-month periods ended March 31, 2021 and 2020. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2021. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities, in these financial statements and accompanying notes. Actual results could differ from these estimates due to the uncertainty around the magnitude and duration of the COVID-19 pandemic, as well as other factors and those differences could have a material effect on our financial position and results of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In December 2019, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This ASU eliminates certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating taxes during the quarters and the recognition of deferred tax liabilities for outside basis differences. The amendments in this update are effective for reporting periods beginning after December 15, 2020, with early adoption permitted. The adoption of this ASU did not have a significant impact on our Consolidated Financial Statements. In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This ASU provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update are elective and subject to meeting certain criteria, that have contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. This could affect balances of right of use assets, lease liabilities, and notes payables. The amendments in this update are effective as of March 12, 2020 through December 21, 2022. The adoption of this ASU is not expected to have a significant impact on our Consolidated Financial Statements.

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Inventory Disclosure [Abstract]
Schedule of composition of inventories	The composition of inventories is as follows (dollar amounts in thousands): March 31, December 31, Raw materials $ 14,075 $ 13,956 Work in progress 1,783 1,351 Finished goods 30,652 32,376 Total inventories $ 46,510 $ 47,683

Net Income Per Share (Tables)

Net Income Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS	Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the Three months ended March 31, 2021 and 2020 (dollar and share amounts in thousands, except for per share information): Three Months Ended 2021 2020 Net income attributable to common shareholders $ 4,016 $ 2,962 Basic weighted average shares outstanding 19,794 19,453 Basic earnings per share attributable to common shareholders $ 0.20 $ 0.15 Diluted shares outstanding: Basic weighted-average shares outstanding 19,794 19,453 Stock-based awards 442 136 Diluted weighted-average shares outstanding 20,236 19,589 Diluted earnings per share attributable to common shareholders $ 0.20 $ 0.15 Dilutive shares excluded from diluted-per-share amounts: Stock options 629 850 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options — 214

Capital Transactions (Tables)

Capital Transactions (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of stock option activity	Stock option activity for the three-month period ended March 31, 2021, is as follows (amounts in thousands, except per share information): Number of Weighted Average Weighted Average Options outstanding at January 1, 2021 226 $ 12.10 $ 5.42 Granted — — — Forfeited or canceled — — — Exercised (2) 11.98 6.16 Options outstanding at March 31, 2021 224 12.10 5.41
Schedule of restricted stock unit activity	Restricted stock unit activity for the three-month period ended March 31, 2021, is as follows (amounts in thousands, except per share information): Number of Weighted Average Restricted Stock Units outstanding at January 1, 2021 1,179 $ 6.18 Granted 229 15.89 Forfeited (30) 11.25 Issued (291) 6.52 Restricted Stock Units outstanding at March 31, 2021 1,087 8.00

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of reportable business segment information	Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended 2021 2020 Net sales: Asia $ 35,755 $ 30,958 Europe 22,200 20,627 North America 37,762 38,757 Latin America and Other 6,704 5,584 Total net sales 102,421 95,926 Contribution margin (1): Asia 15,319 14,527 Europe 6,796 6,831 North America 15,440 14,419 Latin America and Other 3,632 2,450 Total contribution margin 41,187 38,227 Selling, general and administrative expenses (2) 33,552 31,065 Operating income 7,635 7,162 Other loss, net (1,933) (2,410) Income before provision for income taxes $ 5,702 $ 4,752 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2)
Schedule of consolidated net sales revenue by geographical locations	From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three-month periods ended March 31, 2021 and 2020, as follows (dollar amounts in thousands): Three Months Ended 2021 2020 Net sales: United States $ 34,920 $ 35,839 South Korea 14,809 16,389 Other 52,692 43,698 $ 102,421 $ 95,926
Schedule of revenue generated by each of the Company's product lines	Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended 2021 2020 Asia General health $ 11,292 $ 9,046 Immune 203 201 Cardiovascular 9,903 9,339 Digestive 6,871 6,156 Personal care 2,524 3,005 Weight management 4,962 3,211 35,755 30,958 Europe General health $ 9,472 $ 7,961 Immune 2,016 2,444 Cardiovascular 2,992 2,897 Digestive 5,540 4,931 Personal care 1,426 1,751 Weight management 754 643 22,200 20,627 North America General health $ 16,270 $ 15,464 Immune 4,874 7,798 Cardiovascular 4,225 4,167 Digestive 9,463 8,241 Personal care 1,819 1,929 Weight management 1,111 1,158 37,762 38,757 Latin America and Other General health $ 1,976 $ 1,614 Immune 811 809 Cardiovascular 478 378 Digestive 2,870 2,362 Personal care 345 252 Weight management 224 169 6,704 5,584 $ 102,421 $ 95,926
Schedule of consolidated property, plant and equipment by geographical locations	From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): March 31, December 31, Property, plant and equipment: United States $ 48,693 $ 50,025 Other 3,859 4,330 Total property, plant and equipment, net $ 52,552 $ 54,355
Schedule of assets per segment	Total assets per segment is set forth below (dollar amounts in thousands): March 31, December 31, Assets: Asia $ 84,668 $ 82,572 Europe 16,533 16,398 North America 135,710 142,324 Latin America and Other 8,920 8,204 Total assets $ 245,831 $ 249,498

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Schedule of the Company's hierarchy for assets measured at fair value on a recurring basis	The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of March 31, 2021 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 971 $ — $ — $ 971 Total assets measured at fair value on a recurring basis $ 971 $ — $ — $ 971 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2020 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices Significant Significant Total Investment securities - trading $ 989 $ — $ — $ 989 Total assets measured at fair value on a recurring basis $ 989 $ — $ — $ 989

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2021
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset and Liability	The following table presents changes in these contract liability balances for the three-month period ended March 31, 2021 (U.S. dollars in thousands): Outstanding at January 1, 2021 $ 983 Increase (decrease) attributed to: Customer loyalty net deferrals 258 Customer loyalty redemptions (257) Outstanding at March 31, 2021 $ 984

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Noncontrolling Interest [Line Items]
Increase (decrease) in noncontrolling interest	$ 100	$ 44
Noncontrolling interest	1,984		$ 1,848
Restructuring charges	48	$ 100
Accrued Severance and Rent Costs
Noncontrolling Interest [Line Items]
Restructuring Reserve	$ 100		$ 400

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 14,075	$ 13,956
Work in progress	1,783	1,351
Finished goods	30,652	32,376
Total inventories	$ 46,510	$ 47,683

Investment Securities - Tradi_2

Investment Securities - Trading (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Trading securities portfolio	$ 971		$ 989
Debt securities, trading, realized gains (losses)	$ 16	$ (100)

Revolving Credit Facility and_2

Revolving Credit Facility and Other Obligations (Details)	Jun. 11, 2020USD ($)borrowing	Apr. 21, 2020USD ($)payment	Mar. 31, 2021USD ($)	Dec. 31, 2020	Nov. 19, 2020USD ($)	Jul. 11, 2017USD ($)
Revolving credit facility | Bank of America Credit Agreement
Long-term debt
Maximum borrowing capacity						$ 25,000,000
Potential increase in maximum borrowing capacity	$ 15,000,000
Number of separate increases | borrowing	3
Potential increase in maximum borrowing capacity, per occurrence	$ 5,000,000
Annual commitment fee	0.25%
Long-term line of credit			$ 0
Revolving credit facility | LIBOR | Bank of America Credit Agreement
Long-term debt
Margin on variable rate	2.25%
Effective interest rate			2.36%	3.00%
Revolving credit facility | LIBOR | Bank of America Credit Agreement | Minimum
Long-term debt
Margin on variable rate	0.75%
Line of Credit | Banc of America Leasing and Capital Credit Agreement
Long-term debt
Maximum borrowing capacity		$ 6,000,000
Long-term line of credit			$ 3,300,000		$ 3,700,000
Number of monthly payments | payment		36
Periodic payment		$ 100,000
Line of credit, current			$ 1,200,000
Line of Credit | Indicative Index | Banc of America Leasing and Capital Credit Agreement
Long-term debt
Effective interest rate			3.00%

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Earnings Per Share [Abstract]
Net income attributable to common shareholders	$ 4,016	$ 2,962
Basic weighted average shares outstanding (in shares)	19,794	19,453
Basic earnings per share attributable to common shareholders (in dollars per share)	$ 0.20	$ 0.15
Diluted shares outstanding:
Basic weighted-average shares outstanding (in shares)	19,794	19,453
Stock-based awards (in shares)	442	136
Diluted weighted-average shares outstanding (in shares)	20,236	19,589
Diluted earnings per share attributable to common shareholders (in dollars per share)	$ 0.20	$ 0.15
Dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	629	850
Anti-dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	0	214

Capital Transactions - Narrativ

Capital Transactions - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2015	Dec. 31, 2020	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax benefit from the exercise of stock options	$ 0	$ (159,000)
2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)					1,500,000
Additional number of shares authorized under the plan (in shares)			1,500,000
2009 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)	400,000
Options outstanding (in shares)	0
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	224,000			226,000
Share-based compensation expense	$ 0
Unrecognized share-based compensation expense	0			$ 0
Aggregate intrinsic value, outstanding	$ 1,800,000			$ 700,000
Exercised (in shares)	2,500	0
Exercised (in dollars per share)	$ 11.98
Aggregate intrinsic values of options exercised	$ 19,000
Tax benefit from the exercise of stock options	$ 9,000
Time-based stock options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	48 months
Performance based stock options operating income margins
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Operating income margin, one	6.00%
Operating income margin, two	8.00%
Operating income margin, three	10.00%
Unvested stock options outstanding (in shares)	0			0
Performance based stock options operating income margins | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period	1 year
Performance based stock options operating income margins | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period	1 year 3 months
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 400,000	$ 300,000
Unrecognized share-based compensation expense	$ 2,700,000			$ 1,300,000
Discount for lack of marketability	12.70%
Award performance period	3 years
Weighted-average period over which the remaining compensation cost is expected to be recognized	10 months 24 days
Minimum withholding requirements (in shares)	75,000	22,000
RSUs | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	229,000
RSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	50.00%
Risk-free interest rate	0.30%
RSUs | Minimum | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	12 months
RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	54.70%
Risk-free interest rate	2.90%
RSUs | Maximum | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	36 months
RSUs | Director | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restriction period for issuance of shares	2 years
Nonvested subject to restriction period (in shares)	92,000			82,000
Time-Based Restricted Stock Units (RSUs) | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Weighted-average grant date fair value (in dollars per share)	$ 18.34
Performance-Based Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 400,000	$ 100,000
Share based compensation potential compensation expense to be recognized	$ 2,600,000
Performance-Based Restricted Stock Units (RSUs) | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	$ 13.87
Performance-Based Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation potential compensation expense to be recognized	$ 2,700,000
Performance-Based Restricted Stock Units (RSUs) | Net Sales and Operating Income Targets | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years

Capital Transactions - Stock Op

Capital Transactions - Stock Option Activity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Weighted Average Grant Date Fair Value
Options outstanding at the beginning of the period (in dollars per share)	$ 5.42
Options outstanding, exercised (in dollars per share)	6.16
Options outstanding at the end of the period (in dollars per share)	$ 5.41
Stock options
Number of Shares
Options outstanding at the beginning of the period (in shares)	226,000
Granted (in shares)	0
Forfeited or canceled (in shares)	0
Exercised (in shares)	(2,500)	0
Options outstanding at the end of the period (in shares)	224,000
Weighted Average Exercise Price Per Share
Options outstanding at the beginning of the period (in dollars per share)	$ 12.10
Granted (in dollars per share)	0
Forfeited or canceled (in dollars per share)	0
Exercised (in dollars per share)	11.98
Options outstanding at the end of the period (in dollars per share)	$ 12.10

Capital Transactions - RSU Acti

Capital Transactions - RSU Activity (Details) - 2012 Stock Incentive Plan - RSUs	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Number of Shares
Restricted Stock Units outstanding, beginning balance (in shares) | shares	1,179,000
Granted (in shares) | shares	229,000
Forfeited (in shares) | shares	(30,000)
Issued (in shares) | shares	(291,000)
Restricted Stock Units outstanding, ending balance (in shares) | shares	1,087,000
Weighted Average Grant Date Fair Value
Restricted Stock Units outstanding, beginning balance (in dollars per share) | $ / shares	$ 6.18
Granted (in dollars per share) | $ / shares	15.89
Forfeited (in dollars per share) | $ / shares	11.25
Issued (in dollars per share) | $ / shares	6.52
Restricted Stock Units outstanding, ending balance (in dollars per share) | $ / shares	$ 8

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)segment	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
Segment information
Number of business segments | segment	4
Net sales:
Total net sales revenue	$ 102,421	$ 95,926
Contribution margin:
Total contribution margin	41,187	38,227
Selling, general and administrative expenses	33,552	31,065
Operating income	7,635	7,162
Other loss, net	(1,933)	(2,410)
Income before provision for income taxes	5,702	4,752
Total property, plant and equipment, net	52,552		$ 54,355
Total assets	245,831		249,498
Asia
Net sales:
Total net sales revenue	35,755	30,958
Contribution margin:
Total contribution margin	15,319	14,527
Total assets	84,668		82,572
Asia | General health
Net sales:
Total net sales revenue	11,292	9,046
Asia | Immune
Net sales:
Total net sales revenue	203	201
Asia | Cardiovascular
Net sales:
Total net sales revenue	9,903	9,339
Asia | Digestive
Net sales:
Total net sales revenue	6,871	6,156
Asia | Personal care
Net sales:
Total net sales revenue	2,524	3,005
Asia | Weight management
Net sales:
Total net sales revenue	4,962	3,211
Europe
Net sales:
Total net sales revenue	22,200	20,627
Contribution margin:
Total contribution margin	6,796	6,831
Total assets	16,533		16,398
Europe | General health
Net sales:
Total net sales revenue	9,472	7,961
Europe | Immune
Net sales:
Total net sales revenue	2,016	2,444
Europe | Cardiovascular
Net sales:
Total net sales revenue	2,992	2,897
Europe | Digestive
Net sales:
Total net sales revenue	5,540	4,931
Europe | Personal care
Net sales:
Total net sales revenue	1,426	1,751
Europe | Weight management
Net sales:
Total net sales revenue	754	643
North America
Net sales:
Total net sales revenue	37,762	38,757
Contribution margin:
Total contribution margin	15,440	14,419
Total assets	135,710		142,324
North America | General health
Net sales:
Total net sales revenue	16,270	15,464
North America | Immune
Net sales:
Total net sales revenue	4,874	7,798
North America | Cardiovascular
Net sales:
Total net sales revenue	4,225	4,167
North America | Digestive
Net sales:
Total net sales revenue	9,463	8,241
North America | Personal care
Net sales:
Total net sales revenue	1,819	1,929
North America | Weight management
Net sales:
Total net sales revenue	1,111	1,158
Latin America and Other
Net sales:
Total net sales revenue	6,704	5,584
Contribution margin:
Total contribution margin	3,632	2,450
Total assets	8,920		8,204
Latin America and Other | General health
Net sales:
Total net sales revenue	1,976	1,614
Latin America and Other | Immune
Net sales:
Total net sales revenue	811	809
Latin America and Other | Cardiovascular
Net sales:
Total net sales revenue	478	378
Latin America and Other | Digestive
Net sales:
Total net sales revenue	2,870	2,362
Latin America and Other | Personal care
Net sales:
Total net sales revenue	345	252
Latin America and Other | Weight management
Net sales:
Total net sales revenue	224	169
CHINA
Contribution margin:
Selling, general and administrative expenses	2,800	1,900
United States
Net sales:
Total net sales revenue	34,920	35,839
Contribution margin:
Total property, plant and equipment, net	48,693		50,025
South Korea
Net sales:
Total net sales revenue	14,809	16,389
Other
Net sales:
Total net sales revenue	52,692	$ 43,698
Other
Contribution margin:
Total property, plant and equipment, net	$ 3,859		$ 4,330

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Provision for income taxes	27.20%	36.70%
Liability related to unrecognized tax benefits	$ 0.1		$ 0.1

Commitments and Contingencies (

Commitments and Contingencies (Details)	3 Months Ended
	Mar. 31, 2021USD ($)claim	Dec. 31, 2020USD ($)
Value-added tax assessments and other civil litigation
Commitments and contingencies
Minimum number of claims that the Company's insurance coverage may not be sufficient to cover | claim	1
Provision for losses	$ 0
Non-Income Tax Contingencies
Commitments and contingencies
Accrued liabilities	200,000	$ 200,000
Minimum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	0
Minimum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	0
Maximum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	200,000
Maximum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	2,400,000
Pending Litigation
Commitments and contingencies
Accrued liabilities	$ 500,000	$ 500,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
China Joint Venture
Related Party Transaction [Line Items]
Joint venture ownership	80.00%	80.00%
Fosun Pharma | China Joint Venture
Related Party Transaction [Line Items]
Joint venture ownership, noncontrolling party	20.00%	20.00%
NSP China | Subsidiaries | Notes Receivable
Related Party Transaction [Line Items]
Related party transaction, rate	3.00%
China Joint Venture | Subsidiaries | Notes Receivable
Related Party Transaction [Line Items]
Amount of related party transaction	$ 0	$ 0
Due from related parties	4,900,000		$ 4,800,000
China Joint Venture | Subsidiaries | Notes Receivable | Fosun Pharma
Related Party Transaction [Line Items]
Due from related parties	$ 1,200,000		$ 1,200,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Recurring basis - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Total
Fair value
Investment securities - trading	$ 971	$ 989
Total assets measured at fair value on a recurring basis	971	989
Level 1 - Quoted Prices in Active Markets for Identical Assets
Fair value
Investment securities - trading	971	989
Total assets measured at fair value on a recurring basis	971	989
Level 2 - Significant Other Observable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	0	0
Level 3 - Significant Unobservable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	$ 0	$ 0

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details)	3 Months Ended
	Mar. 31, 2021segmentproductCategory
Disaggregation of Revenue [Line Items]
Refund period	90 days
Number of principal categories of products | productCategory	6
Number of business segments | segment	4
Maximum
Disaggregation of Revenue [Line Items]
Contract with customer, contract term	1 year

Revenue Recognition - Changes i

Revenue Recognition - Changes in Contract Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
Change in Contract with Customer, Liability [Roll Forward]
Outstanding at January 1, 2021	$ 983
Increase (decrease) attributed to:
Customer loyalty net deferrals	258
Customer loyalty redemptions	(257)
Outstanding at March 31, 2021	$ 984